The hypothesis that UCP2 is at the crossroads of a metabolic switch is supported by the fact that mutations in UCP2 cause hyperinsulinism [70,71,72] and that increased UCP2 expression is associated with a reduced risk of obesity and type-2 diabetes in humans [73]. Here, UCP2 is linked to obesity disorder.